Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synsorb Biotech (T.SYB) -- Ignore unavailable to you. Want to Upgrade?

To: chevalier who wrote (17)	10/4/1998 7:37:00 AM
From: Reuben Levy	Read Replies (2) \| Respond to of 26

CNN coverage of SynsorbPK... Anyone still following this thread? Yesterday CNN had a Health/Sci feature on Ecoli featuring SynsorbPK. Below is a copy of the story from the the CNN website... Experimental drug offers hope of stopping E. coli infection October 2, 1998 Web posted at: 7:23 p.m. EDT (2323 GMT) From CNN Food & Health Correspondent Linda Ciampa ATLANTA (CNN) -- The Dooley girls are strong and healthy today, but just a few months ago, Marybeth, 6, and Anna, 3, were hospitalized with severe E. coli infections. "They were so sick, they couldn't even hold down sips of water -- no food whatsoever," said their mother, Melissa Dooley. The girls from Hull, Georgia, recovered, and in the process helped doctors learn more about a new drug that may be the first to successfully fight the deadly E. coli bacteria. Both were part of a clinical trial that is testing Synsorb PK. "It acts like a toxin sponge," said David Cox of Synsorb Biotech Inc., the drug's maker. "The compound is taken by the patient. It goes straight to the gut because it can't go anywhere else. "It's an insoluble product, and once in the gut, it specifically reacts with the toxins produced by E. coli -- inactivates the toxin, which is then excreted out of the body as waste." Researchers believe the new drug might be able to prevent E. coli from advancing to its serious and most dangerous state. Even if the infection does progress, Synsorb PK may still be beneficial by reducing the severity of life-threatening complications. "This is a very logical treatment that has a lot of promise, so I am excited about it," said Dr. Barry Warshaw, who treated the Dooleys at Egleston Children's Hospital in Atlanta. "There have been other treatments tried -- specific treatments tried over the years. So far none have panned out." The Dooleys don't know if the new drug will help Marybeth and Anna in their recoveries. They could have received placebos. And they don't know how the girls contracted the bacteria. But the family said they feel good knowing that if final testing of Synsorb PK goes as planned, other children and adults sickened by E. coli could have a new drug by the end of next year.